FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENT	ΛE	CHANCES	INI	<b>BENEFICIAL</b>	OWNEDGUID
SIAILMENI	OF	CHANGES	11.4	BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Swayze Eric  (Last) (First) (Middle)  2855 GAZELLE COURT					_ <u>IC</u> ]	2. Issuer Name and Ticker or Trading Symbol  IONIS PHARMACEUTICALS INC [ IONS ]  3. Date of Earliest Transaction (Month/Day/Year) 12/28/2023								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  EVP Research				
(Street)			92010	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Application)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person											۱		
(City)	(S	ĺ	(Zip)	Jan Davi	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										d to			
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y			tion	n 2A. Deemed Execution Date,		3. 4. Securities		Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amou Securiti Benefic	nount of 6. Or Forr (D) ced Following (I) (II		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			(111541. 4)
Common Stock 12/28/202				2023	23			M		27,100	A	\$47.34	59	,616		D		
Common Stock 12/28/20			2023	23			S		27,100	D	\$50.1875	(1) 32	2,516		D			
Common Stock						73					73		I	by Son				
		-	Table I								posed of,			Owned				
Derivative Conversion Date Execusive or Exercise (Month/Day/Year) if any		if any	emed 4.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		· · · · ·			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	s Blly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to	\$47.34	12/28/2023			M			27,100	01/03	3/2021	01/02/2024	Commor Stock	27,100	\$0.0	0		D	

## **Explanation of Responses:**

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.75 to \$50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

By: Patrick R. O'Neil, attorney-01/02/2024 in-fact For: Eric Swayze

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.